



International health research under Horizon 2020, including international multifunders' initiatives

Global Health Policy Forum

Jacques Delors Building Committee of the Regions (CoR) (meeting room JDE53) Brussels, 12 June 2014 Rosanna D'Amario
Policy Officer of Strategy Unit
Health Directorate
Research & Innovation Directorate General
European Commission



Overview

International

Societal Challenge

Horizon 2020



Cooperation



Health, Demographic Change and Wellbeing











International cooperation in the Health programme under FP7 (2007-2013)





EC contribution by regions/areas









International cooperation

A priority through all Horizon 2020

- Key goal: enhancing and focusing international cooperation in terms of areas and partners
- Objective: 10% of participants in funded projects by 2020
- Horizon 2020 is open to participation from across the world but...
- ... funding to Third countries is not automatic!
 - N.B. Third country = any country not being a Member State, MS, or Associated Country, AC





General opening

Automatic funding:

- MS, AC, International European interest organisations
- Exhaustive list of countries available @ http://ec.europa.eu/research/participants/data/ref/h2020/wp /2014_2015/annexes/h2020-wp1415-annex-a-countriesrules_en.pdf

No automatic funding:

- Australia, Brazil, Canada, China, Japan, India, South Korea, Mexico, New Zealand, Russia, etc.
- International organisations established in Third countries
- Exceptions (article 10 of the Rules for participation and dissemination under Horizon 2020)





What can we expect for collaborative projects under Societal Challenge 1?

- International cooperation is an 'horizontal' issue
 - To be emphasized
- Increase awareness on EC contribution
- Importance of connections established during previous FPs
- Wait for the results from the first call
- Move from bilateral into multilateral...









Multi-lateral health research activities in health research

International K.O. Mouse Consortium

Global Alliance for Chronic Diseases

International Human Epigenome Consortium

International Cancer Genomics Consortium




International Rare Disease Research Consortium

International Initiative for Traumatic Brain Injury Research

International Human Microbiome Consortium New! Global Research
Collaboration for Infectious
Disease Preparedness



How do multi-lateral initiatives work?



Identify common strategic goals

Agree to share tasks (and costs)

Issuing of calls in the cooperating country(ies)

Independent evaluation, selection and funding of projects

Funded projects work closely together

Results, data and standards are being shared



International Rare Diseases Research Consortium (IRDiRC)

200 New Therapies

Means to Diagnose Most Rare Diseases





Committed members

Europe

E-RARE 2 Consortium (EU)

European Commission

EURORDIS (EU)

Academy of Finland

French Muscular Dystrophy Association

French National Research Agency

French Foundation for Rare Diseases

Children's New Hospitals Management Group (GE)

German Federal Ministry of Education and research

Italian Higher Institute of Health Research

Italian Telethon Foundation

Lysogene (FR)

Netherlands Organisation for Health Research and Development

Prosensa (NL)

Spanish Carlos III Health Institute

UK National Institute for Health Research

Australia

Western Australian Dept.

of Health

Asia

BGI (CN)

Chinese Rare Disease Consortium

Korea National Institute of Health



North America

Canadian Institutes for Health Research

Genome Canada

FDA Orphan Products Grants Program

Genetic Alliance (us)

Genzyme (us)

Isis Pharmaceuticals (US)

Mendelian Disorders Genome Centres (US NIH)

National Centre for Translational Sciences (US NIH)

National Cancer Institute (US NIH)

National Institute of Neurological Disorders and Stroke (US NIH)

National Institute of Arthritis and Musculoskeletal and Skin Diseases (US NIH)

National Institute of Child Health and Human Development (US NIH)

National Eye Institute (US NIH)

NKT Therapeutics (US)

NORD (US)

Office of Rare Diseases (US NIH)

PTC Therapeutics (US)

Sanford Research (US)

Shire (us)





IRDiRC Policies & Guidelines

Common framework with separate sections for researchers and funders addressing various aspects of research, such as

- ✓ Sharing of data and samples
- ✓ Rapid release of research results
- ✓ Common quality standards
- ✓ Interoperability and harmonisation of ontologies and bio-banks
- ✓ Involvement of patients





HIRO: Heads of International Research Organisations

- International cooperation connected to cutting-edge research around the world
- Health research funding agencies from several key countries meet regularly and plan common action
- Meetings take place in June and December
- EC RTD Health Director

